37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider ModelByGregory Vidal, MD, PhD,Frank Cinfio,Jack Badaracco,Corey Pelletier,Matthew GitlinJune 22nd 2024